View Future GrowthNRGene Technologies 過去の業績過去 基準チェック /06NRGene Technologiesは15.9%の年平均成長率で業績を伸ばしているが、Software業界はgrowingで24%毎年増加している。売上は減少しており、年平均31.6%の割合である。主要情報15.90%収益成長率19.92%EPS成長率Software 業界の成長15.24%収益成長率-31.63%株主資本利益率-35.30%ネット・マージン-47.38%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Mar 31Full year 2025 earnings released: US$0.12 loss per share (vs US$0.27 loss in FY 2024)Full year 2025 results: US$0.12 loss per share (improved from US$0.27 loss in FY 2024). Revenue: US$3.17m (up 146% from FY 2024). Net loss: US$1.50m (loss narrowed 55% from FY 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 28Full year 2024 earnings released: US$0.27 loss per share (vs US$0.42 loss in FY 2023)Full year 2024 results: US$0.27 loss per share (improved from US$0.42 loss in FY 2023). Revenue: US$1.29m (down 36% from FY 2023). Net loss: US$3.36m (loss narrowed 36% from FY 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.お知らせ • Aug 15NRGene Technologies Ltd to Report Q2, 2024 Results on Aug 20, 2024NRGene Technologies Ltd announced that they will report Q2, 2024 results on Aug 20, 2024お知らせ • Mar 20NRGene Technologies Ltd to Report Q4, 2023 Results on Mar 20, 2024NRGene Technologies Ltd announced that they will report Q4, 2023 results on Mar 20, 2024お知らせ • Aug 17NRGene Technologies Ltd to Report Q2, 2022 Results on Aug 15, 2022NRGene Technologies Ltd announced that they will report Q2, 2022 results on Aug 15, 2022Reported Earnings • Apr 03Full year 2021 earnings released: US$0.69 loss per share (vs US$0.36 loss in FY 2020)Full year 2021 results: US$0.69 loss per share (down from US$0.36 loss in FY 2020). Revenue: US$4.46m (down 37% from FY 2020). Net loss: US$8.34m (loss widened 165% from FY 2020).すべての更新を表示Recent updatesReported Earnings • Mar 31Full year 2025 earnings released: US$0.12 loss per share (vs US$0.27 loss in FY 2024)Full year 2025 results: US$0.12 loss per share (improved from US$0.27 loss in FY 2024). Revenue: US$3.17m (up 146% from FY 2024). Net loss: US$1.50m (loss narrowed 55% from FY 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.New Risk • Mar 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (US$1.2m revenue). Market cap is less than US$100m (₪39.5m market cap, or US$12.8m).New Risk • Dec 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪31.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$10m (₪31.7m market cap, or US$9.88m). Minor Risk Revenue is less than US$5m (US$1.2m revenue).New Risk • Aug 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪32.8m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Market cap is less than US$10m (₪32.8m market cap, or US$9.63m). Minor Risk Revenue is less than US$5m (US$1.3m revenue).お知らせ • May 16NRGene Technologies Ltd, Annual General Meeting, Jun 18, 2025NRGene Technologies Ltd, Annual General Meeting, Jun 18, 2025. Location: company offices, IsraelNew Risk • Apr 05New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪37.1m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Earnings have declined by 1.7% per year over the past 5 years. Market cap is less than US$10m (₪37.1m market cap, or US$9.90m). Minor Risk Revenue is less than US$5m (US$1.3m revenue).Reported Earnings • Mar 28Full year 2024 earnings released: US$0.27 loss per share (vs US$0.42 loss in FY 2023)Full year 2024 results: US$0.27 loss per share (improved from US$0.42 loss in FY 2023). Revenue: US$1.29m (down 36% from FY 2023). Net loss: US$3.36m (loss narrowed 36% from FY 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.New Risk • Mar 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪39.7m market cap, or US$11.0m).New Risk • Dec 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪35.1m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Market cap is less than US$10m (₪35.1m market cap, or US$9.74m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue).New Risk • Dec 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪49.4m market cap, or US$13.6m).New Risk • Aug 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$5.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪44.8m market cap, or US$12.2m).お知らせ • Aug 15NRGene Technologies Ltd to Report Q2, 2024 Results on Aug 20, 2024NRGene Technologies Ltd announced that they will report Q2, 2024 results on Aug 20, 2024New Risk • Aug 05New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (₪48.6m market cap, or US$12.7m).お知らせ • Mar 27NRGene Technologies Ltd, Annual General Meeting, Apr 30, 2024NRGene Technologies Ltd, Annual General Meeting, Apr 30, 2024, at 14:00 Israel Standard Time.お知らせ • Mar 20NRGene Technologies Ltd to Report Q4, 2023 Results on Mar 20, 2024NRGene Technologies Ltd announced that they will report Q4, 2023 results on Mar 20, 2024New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (₪42.6m market cap, or US$11.7m).New Risk • Jan 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (₪37.7m market cap, or US$10.1m).New Risk • Jul 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 22% per year over the past 5 years. Market cap is less than US$10m (₪29.6m market cap, or US$7.96m). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Revenue is less than US$5m (US$3.2m revenue).Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 8 non-independent directors. Independent External Director Oren Mohar was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • Aug 17NRGene Technologies Ltd to Report Q2, 2022 Results on Aug 15, 2022NRGene Technologies Ltd announced that they will report Q2, 2022 results on Aug 15, 2022Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Leah Karmel Goren was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 03Full year 2021 earnings released: US$0.69 loss per share (vs US$0.36 loss in FY 2020)Full year 2021 results: US$0.69 loss per share (down from US$0.36 loss in FY 2020). Revenue: US$4.46m (down 37% from FY 2020). Net loss: US$8.34m (loss widened 165% from FY 2020).お知らせ • Feb 03NRGene and Philoseed Reach Major Milestone Towards Developing ToBRFV High Resistance Tomato VarietiesNRGene and Philoseed announced a major milestone in the development of high resistant tomato varieties to overcome the tomato brown rugose fruit virus – ToBRFV. This advance encompasses the discovery of a unique region in the tomato genome, essential to the tomatoes’ resistance to the virus. The companies are in the process of patent protection of this previously unreported genomic region. The highly contagious tomato virus has been spreading rapidly in Europe, Asia, Africa, and in parts of Mexico and the US, threatening the tomato industry worldwide. This discovery of a unique tomato genomic region is another step forward towards complete resistance solution. It will facilitate the development of DNA markers and seeds of ToBRFV high resistance (HR) tomato varieties and is expected to be completed by the end of 2022. NRGene is currently offering immediate access to the discovered genomic region and DNA markers, and has already signed several commercial contracts, commercializing ToBRFV HR trait with Israeli, European and US companies.お知らせ • Mar 04Nrgene Announces Successful Completion and Results of the Canola/Rapeseed Pan-GenomeNRGene announced the successful completion and results of the canola/rapeseed pan-genome. The International Canola Pan-genome Consortium was established in 2019 to advance the rapeseed agricultural industry by capturing this crop's broad genetic diversity. The global consortium was led jointly by Dr. Isobel Parkin from the Government of Canada’s Agriculture & Agri-food Canada (AAFC), Dr. Andrew Sharpe from the Global Institute for Food Security (GIFS) at the University of Saskatchewan, Canada, and NRGene. The consortium included key players in the canola industry, among them Bayer, Corteva Agriscience, Nutrien Ag Solutions and Nuseed. Each contributed their own canola lines to the research and received the full pangenome comparison results. Rapeseed is a major oil seed crop considered to be a high-quality vegetable oil and commonly used in food production and various industrial applications, including biofuel. According to the United Nation’s Food and Agriculture Organization, rapeseed is farmed on approximately 35 million acres globally and produced 85 million tons in 2019. Canola is the brand name for Canadian rapeseed varieties. Extensive breeding is done globally, focusing on developing higher yielding and more nutritional rapeseed varieties that can naturally resist plant diseases. The use of DNA markers already enhanced canola breeding over the past three decades. Yet, due to canola’s genome complexity, diversity, and instability, the need for a whole genome understanding became a bottleneck in canola breeding. Building a pan-genome database to unravel the broad genomic diversity in canola is the key to expanding the crop’s productivity.お知らせ • Feb 23NRGene and Kayagene Announces Exclusive Agreement for Commercialization of the Autoflower Trait of CannabisNRGene and Kayagene signed an agreement that grants NRGene a world-wide, exclusive license to commercialize the Cannabis autoflower trait and DNA markers linked to it. Utilizing NRGene’s proprietary genomic tools and Kayagene’s proprietary germplasm and breeding knowledge the two companies recently identified the markers associated with the trait. The DNA markers will enable breeders to develop elite autoflower varieties quicker and more efficiently than before. NRGene will offer to license the autoflower trait and linked DNA markers to breeders and growers around the world, while Kayagene will be responsible for delivery of the seeds and pollen harboring the trait.お知らせ • Feb 11NRgene and Kayagene Announces the Completion of Milestone in Their Strategic Research CollaborationNRGene and Kayagene announced the completion of a milestone in their strategic research collaboration. This ongoing collaboration was initiated over 2 years ago, beginning with genomic assembly of several of Kayagene’s cannabis and hemp breeding lines, using NRGene’s DenovoMAGIC™ technology. Now, the companies have successfully mapped several key genes including the autoflowering gene, which is a highly desired trait and of great interest for the hemp and cannabis industries. NRGene estimates, that following the development of DNA markers for the autoflowering trait, it is now possible to integrate this trait into any hemp and cannabis variety within 12 to 18 months. Trait mapping and marker-assisted breeding are vital in a competitive market because it accelerates the time to market for unique and improved varieties harboring those key traits. The use of molecular markers enables rapid and accurate selections and reduces the presence of deleterious genes introduced by traditional breeding methods.収支内訳NRGene Technologies の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史TASE:NRGN 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 253-22130 Sep 252-22230 Jun 251-32231 Mar 251-33231 Dec 241-33230 Sep 241-43230 Jun 242-54131 Mar 242-54231 Dec 232-54230 Sep 232-54230 Jun 233-54231 Mar 233-64231 Dec 223-65230 Sep 223-75330 Jun 224-86431 Mar 224-87431 Dec 214-87430 Sep 215-77330 Jun 216-66331 Mar 217-55331 Dec 207-34230 Sep 207-34230 Jun 207-44231 Mar 207-45231 Dec 198-46231 Dec 187-454質の高い収益: NRGNは現在利益が出ていません。利益率の向上: NRGNは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: NRGNは利益を出していないが、過去 5 年間で年間15.9%の割合で損失を削減してきた。成長の加速: NRGNの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: NRGNは利益が出ていないため、過去 1 年間の収益成長をSoftware業界 ( -12.1% ) と比較することは困難です。株主資本利益率高いROE: NRGNは現在利益が出ていないため、自己資本利益率 ( -35.3% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YSoftware 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 06:39終値2026/05/18 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NRGene Technologies Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Mar 31Full year 2025 earnings released: US$0.12 loss per share (vs US$0.27 loss in FY 2024)Full year 2025 results: US$0.12 loss per share (improved from US$0.27 loss in FY 2024). Revenue: US$3.17m (up 146% from FY 2024). Net loss: US$1.50m (loss narrowed 55% from FY 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 28Full year 2024 earnings released: US$0.27 loss per share (vs US$0.42 loss in FY 2023)Full year 2024 results: US$0.27 loss per share (improved from US$0.42 loss in FY 2023). Revenue: US$1.29m (down 36% from FY 2023). Net loss: US$3.36m (loss narrowed 36% from FY 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
お知らせ • Aug 15NRGene Technologies Ltd to Report Q2, 2024 Results on Aug 20, 2024NRGene Technologies Ltd announced that they will report Q2, 2024 results on Aug 20, 2024
お知らせ • Mar 20NRGene Technologies Ltd to Report Q4, 2023 Results on Mar 20, 2024NRGene Technologies Ltd announced that they will report Q4, 2023 results on Mar 20, 2024
お知らせ • Aug 17NRGene Technologies Ltd to Report Q2, 2022 Results on Aug 15, 2022NRGene Technologies Ltd announced that they will report Q2, 2022 results on Aug 15, 2022
Reported Earnings • Apr 03Full year 2021 earnings released: US$0.69 loss per share (vs US$0.36 loss in FY 2020)Full year 2021 results: US$0.69 loss per share (down from US$0.36 loss in FY 2020). Revenue: US$4.46m (down 37% from FY 2020). Net loss: US$8.34m (loss widened 165% from FY 2020).
Reported Earnings • Mar 31Full year 2025 earnings released: US$0.12 loss per share (vs US$0.27 loss in FY 2024)Full year 2025 results: US$0.12 loss per share (improved from US$0.27 loss in FY 2024). Revenue: US$3.17m (up 146% from FY 2024). Net loss: US$1.50m (loss narrowed 55% from FY 2024). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
New Risk • Mar 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (8.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (US$1.2m revenue). Market cap is less than US$100m (₪39.5m market cap, or US$12.8m).
New Risk • Dec 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪31.7m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.0m free cash flow). Share price has been highly volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$10m (₪31.7m market cap, or US$9.88m). Minor Risk Revenue is less than US$5m (US$1.2m revenue).
New Risk • Aug 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪32.8m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Market cap is less than US$10m (₪32.8m market cap, or US$9.63m). Minor Risk Revenue is less than US$5m (US$1.3m revenue).
お知らせ • May 16NRGene Technologies Ltd, Annual General Meeting, Jun 18, 2025NRGene Technologies Ltd, Annual General Meeting, Jun 18, 2025. Location: company offices, Israel
New Risk • Apr 05New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪37.1m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Earnings have declined by 1.7% per year over the past 5 years. Market cap is less than US$10m (₪37.1m market cap, or US$9.90m). Minor Risk Revenue is less than US$5m (US$1.3m revenue).
Reported Earnings • Mar 28Full year 2024 earnings released: US$0.27 loss per share (vs US$0.42 loss in FY 2023)Full year 2024 results: US$0.27 loss per share (improved from US$0.42 loss in FY 2023). Revenue: US$1.29m (down 36% from FY 2023). Net loss: US$3.36m (loss narrowed 36% from FY 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
New Risk • Mar 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪39.7m market cap, or US$11.0m).
New Risk • Dec 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₪35.1m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Market cap is less than US$10m (₪35.1m market cap, or US$9.74m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue).
New Risk • Dec 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Share price has been highly volatile over the past 3 months (7.4% average weekly change). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪49.4m market cap, or US$13.6m).
New Risk • Aug 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$5.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.9m free cash flow). Earnings have declined by 6.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Revenue is less than US$5m (US$1.6m revenue). Market cap is less than US$100m (₪44.8m market cap, or US$12.2m).
お知らせ • Aug 15NRGene Technologies Ltd to Report Q2, 2024 Results on Aug 20, 2024NRGene Technologies Ltd announced that they will report Q2, 2024 results on Aug 20, 2024
New Risk • Aug 05New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (₪48.6m market cap, or US$12.7m).
お知らせ • Mar 27NRGene Technologies Ltd, Annual General Meeting, Apr 30, 2024NRGene Technologies Ltd, Annual General Meeting, Apr 30, 2024, at 14:00 Israel Standard Time.
お知らせ • Mar 20NRGene Technologies Ltd to Report Q4, 2023 Results on Mar 20, 2024NRGene Technologies Ltd announced that they will report Q4, 2023 results on Mar 20, 2024
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (₪42.6m market cap, or US$11.7m).
New Risk • Jan 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Earnings have declined by 15% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (₪37.7m market cap, or US$10.1m).
New Risk • Jul 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 22% per year over the past 5 years. Market cap is less than US$10m (₪29.6m market cap, or US$7.96m). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Revenue is less than US$5m (US$3.2m revenue).
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 1 independent director. 8 non-independent directors. Independent External Director Oren Mohar was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • Aug 17NRGene Technologies Ltd to Report Q2, 2022 Results on Aug 15, 2022NRGene Technologies Ltd announced that they will report Q2, 2022 results on Aug 15, 2022
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Leah Karmel Goren was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 03Full year 2021 earnings released: US$0.69 loss per share (vs US$0.36 loss in FY 2020)Full year 2021 results: US$0.69 loss per share (down from US$0.36 loss in FY 2020). Revenue: US$4.46m (down 37% from FY 2020). Net loss: US$8.34m (loss widened 165% from FY 2020).
お知らせ • Feb 03NRGene and Philoseed Reach Major Milestone Towards Developing ToBRFV High Resistance Tomato VarietiesNRGene and Philoseed announced a major milestone in the development of high resistant tomato varieties to overcome the tomato brown rugose fruit virus – ToBRFV. This advance encompasses the discovery of a unique region in the tomato genome, essential to the tomatoes’ resistance to the virus. The companies are in the process of patent protection of this previously unreported genomic region. The highly contagious tomato virus has been spreading rapidly in Europe, Asia, Africa, and in parts of Mexico and the US, threatening the tomato industry worldwide. This discovery of a unique tomato genomic region is another step forward towards complete resistance solution. It will facilitate the development of DNA markers and seeds of ToBRFV high resistance (HR) tomato varieties and is expected to be completed by the end of 2022. NRGene is currently offering immediate access to the discovered genomic region and DNA markers, and has already signed several commercial contracts, commercializing ToBRFV HR trait with Israeli, European and US companies.
お知らせ • Mar 04Nrgene Announces Successful Completion and Results of the Canola/Rapeseed Pan-GenomeNRGene announced the successful completion and results of the canola/rapeseed pan-genome. The International Canola Pan-genome Consortium was established in 2019 to advance the rapeseed agricultural industry by capturing this crop's broad genetic diversity. The global consortium was led jointly by Dr. Isobel Parkin from the Government of Canada’s Agriculture & Agri-food Canada (AAFC), Dr. Andrew Sharpe from the Global Institute for Food Security (GIFS) at the University of Saskatchewan, Canada, and NRGene. The consortium included key players in the canola industry, among them Bayer, Corteva Agriscience, Nutrien Ag Solutions and Nuseed. Each contributed their own canola lines to the research and received the full pangenome comparison results. Rapeseed is a major oil seed crop considered to be a high-quality vegetable oil and commonly used in food production and various industrial applications, including biofuel. According to the United Nation’s Food and Agriculture Organization, rapeseed is farmed on approximately 35 million acres globally and produced 85 million tons in 2019. Canola is the brand name for Canadian rapeseed varieties. Extensive breeding is done globally, focusing on developing higher yielding and more nutritional rapeseed varieties that can naturally resist plant diseases. The use of DNA markers already enhanced canola breeding over the past three decades. Yet, due to canola’s genome complexity, diversity, and instability, the need for a whole genome understanding became a bottleneck in canola breeding. Building a pan-genome database to unravel the broad genomic diversity in canola is the key to expanding the crop’s productivity.
お知らせ • Feb 23NRGene and Kayagene Announces Exclusive Agreement for Commercialization of the Autoflower Trait of CannabisNRGene and Kayagene signed an agreement that grants NRGene a world-wide, exclusive license to commercialize the Cannabis autoflower trait and DNA markers linked to it. Utilizing NRGene’s proprietary genomic tools and Kayagene’s proprietary germplasm and breeding knowledge the two companies recently identified the markers associated with the trait. The DNA markers will enable breeders to develop elite autoflower varieties quicker and more efficiently than before. NRGene will offer to license the autoflower trait and linked DNA markers to breeders and growers around the world, while Kayagene will be responsible for delivery of the seeds and pollen harboring the trait.
お知らせ • Feb 11NRgene and Kayagene Announces the Completion of Milestone in Their Strategic Research CollaborationNRGene and Kayagene announced the completion of a milestone in their strategic research collaboration. This ongoing collaboration was initiated over 2 years ago, beginning with genomic assembly of several of Kayagene’s cannabis and hemp breeding lines, using NRGene’s DenovoMAGIC™ technology. Now, the companies have successfully mapped several key genes including the autoflowering gene, which is a highly desired trait and of great interest for the hemp and cannabis industries. NRGene estimates, that following the development of DNA markers for the autoflowering trait, it is now possible to integrate this trait into any hemp and cannabis variety within 12 to 18 months. Trait mapping and marker-assisted breeding are vital in a competitive market because it accelerates the time to market for unique and improved varieties harboring those key traits. The use of molecular markers enables rapid and accurate selections and reduces the presence of deleterious genes introduced by traditional breeding methods.